MediWound (NASDAQ:MDWD) Raised to Sell at StockNews.com

MediWound (NASDAQ:MDWD) was upgraded by StockNews.com to a “sell” rating in a note issued to investors on Wednesday.

Separately, HC Wainwright reiterated a “buy” rating and set a $28.00 price objective on shares of MediWound in a research note on Thursday, May 30th.

MediWound Trading Down 6.7 %

Shares of MDWD stock opened at $14.51 on Wednesday. The company has a market capitalization of $134.65 million, a price-to-earnings ratio of -10.51 and a beta of 0.81. The firm has a 50-day moving average price of $16.58 and a 200 day moving average price of $14.73. MediWound has a twelve month low of $7.10 and a twelve month high of $19.86.

MediWound (NASDAQ:MDWD) last issued its quarterly earnings results on Wednesday, May 29th. The biopharmaceutical company reported ($0.39) EPS for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.01. MediWound had a negative net margin of 64.24% and a negative return on equity of 21.67%. The business had revenue of $4.96 million during the quarter, compared to the consensus estimate of $4.65 million. As a group, research analysts predict that MediWound will post -1.93 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in MDWD. Janney Montgomery Scott LLC purchased a new position in MediWound during the 1st quarter valued at about $427,000. Silverberg Bernstein Capital Management LLC acquired a new stake in shares of MediWound during the fourth quarter worth approximately $803,000. Sargent Investment Group LLC boosted its holdings in shares of MediWound by 7.0% during the fourth quarter. Sargent Investment Group LLC now owns 109,194 shares of the biopharmaceutical company’s stock worth $1,111,000 after purchasing an additional 7,125 shares during the period. Yelin Lapidot Holdings Management Ltd. grew its position in MediWound by 45.7% during the fourth quarter. Yelin Lapidot Holdings Management Ltd. now owns 125,493 shares of the biopharmaceutical company’s stock valued at $1,276,000 after purchasing an additional 39,348 shares in the last quarter. Finally, Essex Investment Management Co. LLC increased its stake in MediWound by 241.6% in the 1st quarter. Essex Investment Management Co. LLC now owns 132,487 shares of the biopharmaceutical company’s stock valued at $1,888,000 after buying an additional 93,705 shares during the period. 46.83% of the stock is currently owned by institutional investors and hedge funds.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.